Niagen BioscienceNAGE
NAGE logo
Fair Value
US$21.2
Share price29 Jul
US$3.0485.7% undervalued intrinsic discount
Loading
1Y-69.96%
7D-0.33%

Expanding NAD Category And Clinical Pipeline Will Drive Powerful Long-Term Upside

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published
04 Jan 26
Updated
29 Jul 26
Views
89
Not Invested

Shared on 29 Jul 26

Fair value Increased 18%

NAGE: Longevity And GLP-1 Wellness Tailwinds Will Support Future Upside

Read more
5 viewsusers have viewed this narrative update

Shared on 30 Jun 26

Fair value Decreased 22%

NAGE: Future Execution On Telehealth Platform Will Drive Upside Potential

Read more
11 viewsusers have viewed this narrative update

Fair Value vs Share Price

US$21.2
vs US$3.0485.7% undervalued intrinsic discount
PastFuture-33m225m2015201820212024202620272029Revenue US$224.6mEarnings US$40.7m
19.9%
Revenue growth
18.1%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Niagen Bioscience

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet and fair value.

Market capUS$239.5m
PB2.9x
Estimated Growth14.2%
Dividend YieldN/A
Full analysis

CEO & management

Robert Fried
CEO
6.5yrs
CEO Tenure

Operates as a bioscience company engages in developing healthy aging products.